Trian Comments on Solventum’s Sale of its Purification & Filtration Business
27 2월 2025 - 4:50AM
Trian Fund Management, L.P. (“Trian”), which beneficially owns ~5%
of Solventum Corporation (NYSE: SOLV) (“Solventum” or the
“Company”) and is the Company’s largest active shareholder,
commented on Solventum’s recently announced sale of its
Purification & Filtration business to Thermo Fisher Scientific
Inc (NYSE: TMO) (“Thermo Fisher”). Trian issued the following
statement:
“Trian commends Solventum on the announced sale
of its Purification & Filtration business and believes this is
an important first step in the Company’s value creation journey. We
believe that part of what attracted strategic interest at such a
high valuation multiple was the division’s differentiated
technology and material science – attributes inherited from 3M
which are present at Solventum’s remaining businesses, and which we
believe remain underappreciated by the market today.
Notably, in conjunction with the acquisition,
Thermo Fisher issued public comments which Trian believes confirm
that there is a meaningful cost reduction opportunity at
Solventum:
“Excluding financing
costs, the transaction is expected to be accretive by $0.28 in that
period. This reflects the very strong day one cost synergies when
Solventum’s allocated segment costs are replaced by lower run rate
costs within Thermo Fisher.”
Thermo Fisher’s release goes on to suggest that
it believes it can more than double the profitability of
Purification & Filtration under its corporate umbrella,
relative to the business’ current profit as part of Solventum, with
much of that improvement driven by lower allocated costs.
Trian, in its January letter to shareholders,
highlighted that Solventum has a significant opportunity to right
size costs and realize higher margins while reinvesting more in
growth.
Inside of 3M, Solventum averaged 3-4% organic
growth and a 26-27% EBIT margin. Trian believes that Solventum
should be able to deliver faster organic growth and higher margins
as a focused, standalone company. Trian looks forward to the
Company delivering a Long Range Plan that reflects the business’
potential when it hosts its investor day in March.”
About Trian Fund Management,
L.P. Founded in 2005, Trian Fund Management, L.P.
(“Trian”) is a multi-billion dollar investment management firm.
Trian is a highly engaged shareowner that combines concentrated
public equity ownership with operational expertise. Leveraging the
50+ years’ operating experience of our Founding Partners, Nelson
Peltz and Peter May, Trian seeks to invest in high quality but
undervalued and underperforming public companies and to work
collaboratively with management teams and boards to help companies
execute operational and strategic initiatives designed to drive
long-term sustainable earnings growth for the benefit of all
shareholders.
Media Contacts: Anne A.
Tarbell(212) 451-3030atarbell@trianpartners.com
Paul Caminiti / Pamela Greene / Jacqueline
ZuhseReevemark(212) 433-4600Trian@reevemark.com
Investor Contact: Matt
Underhill(212) 451-3171munderhill@trianpartners.com
Disclaimer
Except as otherwise set forth in this press
release, the views expressed in this press release reflect the
opinions of Trian Fund Management, L.P. and its affiliates
(“Trian”), and are based on publicly available information with
respect to Solventum Corporation (the “Company”). Trian recognizes
that there may be confidential information in the possession of the
Company that could lead it or others to disagree with Trian’s
conclusions. Trian reserves the right to change any of its opinions
expressed herein at any time as it deems appropriate and disclaims
any obligation to notify the market or any other party of any such
change, except as required by law. Trian disclaims any obligation
to update the information or opinions contained in this press
release. For the avoidance of doubt, this press release is not
affiliated with or endorsed by the Company.
This press release is provided merely as
information and is not intended to be, nor should it be construed
as, an offer to sell or a solicitation of an offer to buy any
security nor as a recommendation to purchase or sell any security.
Funds managed by Trian currently beneficially own shares of the
Company. These funds are in the business of trading – buying and
selling– securities and intend to continue trading in the
securities of the Company. You should assume such funds may from
time to time sell all or a portion of their holdings of the Company
in open market transactions or otherwise (including via short
sales), buy additional shares (in open market or privately
negotiated transactions or otherwise), or trade in options, puts,
calls, swaps or other derivative instruments relating to such
shares.
Some of the materials in this press release
contain forward-looking statements. All statements contained herein
that are not clearly historical in nature or that necessarily
depend on future events are forward-looking, and the words
“anticipate,” “believe,” “expect,” “potential,” “could,”
“opportunity,” “estimate,” “plan,” and similar expressions are
generally intended to identify forward-looking statements. The
projected results and statements contained herein that are not
historical facts are based on current expectations, speak only as
of the date of these materials and involve risks, uncertainties and
other factors that may cause actual results, performances or
achievements to be materially different from any future results,
performances or achievements expressed or implied by such projected
results and statements. Assumptions relating to the foregoing
involve judgments with respect to, among other things, future
economic competitive and market conditions and future business
decisions, all of which are difficult or impossible to predict
accurately and many of which are beyond the control of Trian.
Certain financial projections and statements
made herein have been derived or obtained from filings made with
the Securities and Exchange Commission (“SEC”) or other regulatory
authorities and from other third-party reports. Trian shall not be
responsible or have any liability for any misinformation contained
in any third-party, SEC or other regulatory filing or third-party
report.
There is no assurance or guarantee with respect
to the prices at which any securities of the Company will trade,
and such securities may not trade at prices that may be implied
herein. The estimates, projections and potential impact of the
opportunities identified by Trian herein are based on assumptions
that Trian believes to be reasonable as of the date of this press
release, but there can be no assurance or guarantee (i) that any of
the proposed actions set forth in this press release will be
completed, (ii) that the actual results or performance of the
Company will not differ, and such differences may be material, or
(iii) that any of the assumptions provided in this press release
are accurate. This press release does not recommend the
purchase or sale of any security.
Thermo Fisher Scientific (NYSE:TMO)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025
Thermo Fisher Scientific (NYSE:TMO)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025